Not Signed In -
Epidemiology & Prevention of Vaccine-Preventable Diseases |
Pink Book |
Clinical Trial: Genetic Epidemiology of Responses to Antihypertensives
This study is no longer recruiting patients.
Purpose
To determine whether measured variation in genes coding for components of the renin-angiotensin-aldosterone (RAA) system predicts interindividual differences in blood pressure response to diuretic therapy in 300 hypertensive African-Americans and in 300 hypertensive non-Hispanic whites.
| Condition |
|---|
| Cardiovascular Diseases Heart Diseases Hypertension |
MedlinePlus related topics: Heart Diseases; Heart Diseases--Prevention; High Blood Pressure; Vascular Diseases
Study Type: Observational
Study Design: Natural History
Study start: February 1997; Study completion: January 2007
BACKGROUND: Essential hypertension is a common disorder that contributes to morbidity, mortality, and cost of health care, especially among African-Americans. Although diuretics are commonly prescribed for treatment of hypertension, blood pressure decreases in response to diuretic therapy in some individuals but not in others. The study has the potential to identify genes contributing to the etiology of interindividual differences in blood pressure response to diuretic therapy in African-Americans and in non-Hispanic whites.
DESIGN NARRATIVE: Hypertensive adults are treated with the diuretic hydrochlorothiazide, 25 mg/day, for four weeks. Interindividual variations are measured in five RAA system genes-- angiotensinogen, renin, angiotensin-1 converting enzyme, angiotensin-II receptor, and aldosterone synthase --to accomplish the following specific aims in each ethnic group. The first aim is to determine whether variation in genes of the RAA system predicts interindividual differences in blood pressure response to diuretic therapy. The second aim is to determine whether variation in genes of the RAA system predicts interindividual differences in baseline measures of the endocrine RAA system or response of these measures to diuretic therapy. The third aid is to determine whether the predictive effects of variations in genes of the RAA system on blood pressure response to diuretic therapy detected in Aim 1 are mediated through their effects on baseline measures of the endocrine RAA system or response of these measures to diuretic therapy, detected in Aim 2.
Eligibility
Genders Eligible for Study: Male
Criteria
Location Information
Stephen Turner, Mayo Foundation
More Information
Publications
Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001 Feb;37(2 Part 2):739-43.
Turner ST, Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation. 2000 Nov 14;102(20 Suppl 4):IV40-5. Review. No abstract available.
Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens. 2001 Jan;19(1):1-11. Review.
Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001 Sep;76(9):877-82.
Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Use of gene markers to guide antihypertensive therapy. Curr Hypertens Rep. 2001 Oct;3(5):410-5. Review.
Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002 Nov;48(11):1919-23.
Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol. 2003 Jan 15;546(Pt 2):583-9.
Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics. 2003 Jan;4(1):53-65. Review.
Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics. 2004;4(3):151-60. Review.
Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J. 2004;4(1):17-23.
Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct;16(10):834-9.
Record last reviewed: January 2005
Last Updated: February 3, 2005
Record first received: May 25, 2000
ClinicalTrials.gov Identifier: NCT00005520
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Epidemiology & Prevention of Vaccine-Preventable Diseases (Centers for Disease Control and Prevention)
email this page
print this page
bookmark this page
feedback on this page
